Fractyl’s Revita DMR Significantly Improves Hyperglycemia in Type 2 Diabetes Patients

Fractyl’s Revita DMR Significantly Improves Hyperglycemia in Type 2 Diabetes Patients

This post was originally published on this site

Fractyl Laboratories Inc. announced today publication of data in the current issue of Diabetes Care from the Company’s first-in-human study of RevitaTM duodenal mucosal resurfacing . “Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis from the First-in-Human Proof-of-Concept Study” is the first comprehensive analysis and publication of data from 39 patients in the first-in-human Revita DMR trial.